Follow
Yu Amanda Guo
Yu Amanda Guo
Genome Institute of Singapore
Verified email at cornell.edu
Title
Cited by
Cited by
Year
Mutation hotspots at CTCF binding sites coupled to chromosomal instability in gastrointestinal cancers
YA Guo, MM Chang, W Huang, WF Ooi, M Xing, P Tan, AJ Skanderup
Nature communications 9 (1), 1520, 2018
1502018
Single-cell and bulk transcriptome sequencing identifies two epithelial tumor cell states and refines the consensus molecular classification of colorectal cancer
I Joanito, P Wirapati, N Zhao, Z Nawaz, G Yeo, F Lee, CLP Eng, ...
Nature genetics 54 (7), 963-975, 2022
1462022
Developmental plasticity is bound by pluripotency and the Fgf and Wnt signaling pathways
SA Morris, Y Guo, M Zernicka-Goetz
Cell reports 2 (4), 756-765, 2012
1172012
Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma
D Kerdidani, P Chouvardas, AR Arjo, I Giopanou, G Ntaliarda, YA Guo, ...
Nature communications 10 (1), 1405, 2019
762019
Tissue-specific cell-free DNA degradation quantifies circulating tumor DNA burden
G Zhu, YA Guo, D Ho, P Poon, ZW Poh, PM Wong, A Gan, MM Chang, ...
Nature communications 12 (1), 2229, 2021
602021
Dissecting disease inheritance modes in a three-dimensional protein network challenges the “guilt-by-association” principle
Y Guo, X Wei, J Das, A Grimson, SM Lipkin, AG Clark, H Yu
The American Journal of Human Genetics 93 (1), 78-89, 2013
512013
Pan-Cancer Analysis of Ligand–Receptor Cross-talk in the Tumor Microenvironment
U Ghoshdastider, N Rohatgi, M Mojtabavi Naeini, P Baruah, E Revkov, ...
Cancer research 81 (7), 1802-1812, 2021
502021
Integrated paired-end enhancer profiling and whole-genome sequencing reveals recurrent CCNE1 and IGF2 enhancer hijacking in primary gastric adenocarcinoma
WF Ooi, AM Nargund, KJ Lim, S Zhang, M Xing, A Mandoli, JQ Lim, ...
Gut 69 (6), 1039-1052, 2020
462020
Heritability and inter-population differences in lipid profiles of Drosophila melanogaster
CJF Scheitz, Y Guo, AM Early, LG Harshman, AG Clark
PLoS One 8 (8), e72726, 2013
432013
Whole-genome noncoding sequence analysis in T-cell acute lymphoblastic leukemia identifies oncogene enhancer mutations
S Hu, M Qian, H Zhang, Y Guo, J Yang, X Zhao, H He, J Lu, J Pan, ...
Blood, The Journal of the American Society of Hematology 129 (24), 3264-3268, 2017
402017
Exploring mechanisms of human disease through structurally resolved protein interactome networks
J Das, R Fragoza, HR Lee, NA Cordero, Y Guo, MJ Meyer, TV Vo, X Wang, ...
Molecular BioSystems 10 (1), 9-17, 2014
292014
Integrated network analysis reveals distinct regulatory roles of transcription factors and microRNAs
Y Guo, K Alexander, AG Clark, A Grimson, H Yu
RNA 22 (11), 1663-1672, 2016
272016
Epigenetic promoter alterations in GI tumour immune-editing and resistance to immune checkpoint inhibition
R Sundar, KK Huang, V Kumar, K Ramnarayanan, D Demircioglu, Z Her, ...
Gut 71 (7), 1277-1288, 2022
252022
SMuRF: portable and accurate ensemble prediction of somatic mutations
W Huang, YA Guo, K Muthukumar, P Baruah, MM Chang, ...
Bioinformatics 35 (17), 3157-3159, 2019
242019
Regulatory enhancer profiling of mesenchymal-type gastric cancer reveals subtype-specific epigenomic landscapes and targetable vulnerabilities
SWT Ho, T Sheng, M Xing, WF Ooi, C Xu, R Sundar, KK Huang, Z Li, ...
Gut 72 (2), 226-241, 2023
172023
Genomic and epigenomic EBF1 alterations modulate TERT expression in gastric cancer
M Xing, WF Ooi, J Tan, A Qamra, PH Lee, Z Li, C Xu, N Padmanabhan, ...
The Journal of Clinical Investigation 130 (6), 3005-3020, 2020
162020
MutSpot: detection of non-coding mutation hotspots in cancer genomes
YA Guo, MM Chang, AJ Skanderup
NPJ genomic medicine 5 (1), 26, 2020
132020
Integrative epigenomic and high-throughput functional enhancer profiling reveals determinants of enhancer heterogeneity in gastric cancer
T Sheng, SWT Ho, WF Ooi, C Xu, M Xing, N Padmanabhan, KK Huang, ...
Genome Medicine 13 (1), 1-25, 2021
112021
Wnt1 silences chemokine genes in dendritic cells and induces adaptive immune resistance in lung adenocarcinoma. Nat Commun. 2019
D Kerdidani, P Chouvardas, AR Arjo, I Giopanou, G Ntaliarda, YA Guo
11
A randomized phase 2 trial of nivolumab versus nivolumab-ipilimumab combination in EGFR-mutant NSCLC
GGY Lai, JC Yeo, A Jain, S Zhou, M Pang, JJS Alvarez, NL Sim, AC Tan, ...
JTO Clinical and Research Reports 3 (12), 100416, 2022
72022
The system can't perform the operation now. Try again later.
Articles 1–20